TOR Serine-Threonine Kinases

"TOR Serine-Threonine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A serine threonine kinase that controls a wide range of growth-related cellular processes. The protein is referred to as the target of RAPAMYCIN due to the discovery that SIROLIMUS (commonly known as rapamycin) forms an inhibitory complex with TACROLIMUS BINDING PROTEIN 1A that blocks the action of its enzymatic activity.

Descriptor ID	D058570
MeSH Number(s)	D08.811.913.696.620.682.700.931 D12.776.476.925
Concept/Terms	TOR Serine-Threonine Kinases TOR Serine-Threonine Kinases Kinases, TOR Serine-Threonine Serine-Threonine Kinases, TOR TOR Serine Threonine Kinases Target of Rapamycin Proteins Rapamycin Proteins Target mTOR Serine-Threonine Kinases Kinases, mTOR Serine-Threonine Serine-Threonine Kinases, mTOR mTOR Serine Threonine Kinases Mechanistic Target of Rapamycin Protein FK506 Binding Protein 12-Rapamycin Associated Protein 1 FK506 Binding Protein 12 Rapamycin Associated Protein 1 TOR Kinases FKBP12-Rapamycin Associated Protein Associated Protein, FKBP12-Rapamycin FKBP12 Rapamycin Associated Protein Protein, FKBP12-Rapamycin Associated FKBP12-Rapamycin Complex-Associated Protein Complex-Associated Protein, FKBP12-Rapamycin FKBP12 Rapamycin Complex Associated Protein Protein, FKBP12-Rapamycin Complex-Associated RAFT-1 Protein Protein, RAFT-1 RAFT 1 Protein Rapamycin Target Protein Protein, Rapamycin Target Target Protein, Rapamycin mTOR Protein Protein, mTOR

Below are MeSH descriptors whose meaning is more general than "TOR Serine-Threonine Kinases".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Serine-Threonine Kinases [D08.811.913.696.620.682.700]
TOR Serine-Threonine Kinases [D08.811.913.696.620.682.700.931]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Intracellular Signaling Peptides and Proteins [D12.776.476]
TOR Serine-Threonine Kinases [D12.776.476.925]

Below are MeSH descriptors whose meaning is related to "TOR Serine-Threonine Kinases".

Below are MeSH descriptors whose meaning is more specific than "TOR Serine-Threonine Kinases".

TOR Serine-Threonine Kinases
Mechanistic Target of Rapamycin Complex 1
Mechanistic Target of Rapamycin Complex 2

publications

Timeline | Most Recent

This graph shows the total number of publications written about "TOR Serine-Threonine Kinases" by people in this website by year, and whether "TOR Serine-Threonine Kinases" was a major or minor topic of these publications.

Bar chart showing 82 publications over 20 distinct years, with a maximum of 14 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	1	1
2004	0	1	1
2006	0	3	3
2007	0	6	6
2008	0	1	1
2009	0	6	6
2010	0	7	7
2011	3	4	7
2012	1	3	4
2013	2	2	4
2014	6	8	14
2015	1	2	3
2016	2	4	6
2017	0	2	2
2018	0	4	4
2019	1	1	2
2020	2	1	3
2021	3	0	3
2022	0	4	4
2023	0	1	1

Below are the most recent publications written about "TOR Serine-Threonine Kinases" by people in Profiles.

Meredith L, Chao T, Nevler A, Basu Mallick A, Singla RK, McCue PA, Bowne WB, Jiang W. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report. Diagn Pathol. 2023 Apr 11; 18(1):45.

View in: PubMed
Hernandez-Lara MA, Yadav SK, Shah SD, Okumura M, Yokoyama Y, Penn RB, Kambayashi T, Deshpande DA. Regulation of Airway Smooth Muscle Cell Proliferation by Diacylglycerol Kinase: Relevance to Airway Remodeling in Asthma. Int J Mol Sci. 2022 Oct 06; 23(19).

View in: PubMed
Chlopek M, Lasota J, Thompson LDR, Szczepaniak M, Kuzniacka A, Hincza K, Kubicka K, Kaczorowski M, Newford M, Liu Y, Agaimy A, Biernat W, Durzynska M, Dziuba I, Hartmann A, Inaguma S, Izycka-Swieszewska E, Kato H, Kopczynski J, Michal M, Michal M, Peksa R, Prochorec-Sobieszek M, Starzynska A, Takahashi S, Wasag B, Kowalik A, Miettinen M. Alterations in key signaling pathways in sinonasal tract melanoma. A molecular genetics and immunohistochemical study of 90 cases and comprehensive review of the literature. Mod Pathol. 2022 11; 35(11):1609-1617.

View in: PubMed
Moellmann J, Mann PA, Kappel BA, Kahles F, Klinkhammer BM, Boor P, Kramann R, Ghesquiere B, Lebherz C, Marx N, Lehrke M. The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis. Diabetes Obes Metab. 2022 11; 24(11):2263-2272.

View in: PubMed
Wang D, Eisen HJ. Mechanistic Target of Rapamycin (mTOR) Inhibitors. Handb Exp Pharmacol. 2022; 272:53-72.

View in: PubMed
Cao M, Luo X, Wu K, He X. Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduct Target Ther. 2021 11 08; 6(1):379.

View in: PubMed
Kar AN, Lee SJ, Sahoo PK, Thames E, Yoo S, Houle JD, Twiss JL. MicroRNAs 21 and 199a-3p Regulate Axon Growth Potential through Modulation of Pten and mTor mRNAs. eNeuro. 2021 Jul-Aug; 8(4).

View in: PubMed
Pathak P, Blech-Hermoni Y, Subedi K, Mpamugo J, Obeng-Nyarko C, Ohman R, Molloy I, Kates M, Hale J, Stauffer S, Sharan SK, Mankodi A. Myopathy associated LDB3 mutation causes Z-disc disassembly and protein aggregation through PKCa and TSC2-mTOR downregulation. Commun Biol. 2021 03 19; 4(1):355.

View in: PubMed
Gnanapradeepan K, Leu JI, Basu S, Barnoud T, Good M, Lee JV, Quinn WJ, Kung CP, Ahima R, Baur JA, Wellen KE, Liu Q, Schug ZT, George DL, Murphy ME. Increased mTOR activity and metabolic efficiency in mouse and human cells containing the African-centric tumor-predisposing p53 variant Pro47Ser. Elife. 2020 11 10; 9.

View in: PubMed
Eisen HJ. CAVEAT mTOR: You've heard about the benefits of using mTOR inhibitors, here are some of the risks. Am J Transplant. 2021 02; 21(2):449-450.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement